Companies Cryptocurrencies
Satsuma Pharmaceuticals Inc
Satsuma Pharmaceuticals Inc
Exchange: NasdaqGS
IPO Date: 13/09/2019
CEO: Mr. John Kollins
Biotechnology Healthcare 🔗
  • STSA
  • 5.995
  • 189367056
    market cap
  • 0.20499992
If you bought

shares of Satsuma Pharmaceuticals Inc (STSA) on
You would have made
Old Price $12 Current Price $12

Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in South San Francisco, California and currently employs 16 full-time employees. The firm is focused on developing a therapeutic product for the treatment of migraine. The Company’s product candidate STS101, is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate (DHE), which can be self-administered with a proprietary pre-filled, single-use, nasal delivery device.

Address: 400 Oyster Point Blvd Ste 221 South San Francisco CALIFORNIA 94080

Stay updated.